Olema Pharmaceuticals (OLMA): היקף יתרות המזומנים של החברה

Olema Pharmaceuticals (OLMA) is establishing a market barrier through patents for innovative breast cancer treatments. Growth potential is driven by its partnership with Novartis and the success of palocsertib. The business is non-cyclical but requires investment. The cash balance history illustrates liquidity dynamics, where 0.41 serves as the current metric, determining the company's financial cushion.
פילוחי מדדים פיננסיים ומדדי שוק עבור Olema (OLMA)

This metric aggregates liquid assets and cash equivalents on the balance sheet, determining the issuer's ability to avoid cash flow gaps and maintain financial stability without external borrowing. For Olema Pharmaceuticals (OLMA), this reserve is critical for financing costly joint clinical trials of palvestrant and acquiring biotech patents, which is clearly evidenced by the cash trend.